The EAP launch is a modest positive for patient access optics but does not derisk APOLLO. Key binary catalyst is APOLLO topline data in Q4 2026; the mid-2027 FDA decision timeline reinforces that near-term stock movement will be driven by Phase 3 results, not today's announcement. Traders should focus on APOLLO enrollment and data timing updates.
IRON drugs
IRON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $71.97entry
- T+1 · 6mo ago −5.52%α −5.66% · $68.00
- T+5 · 5mo ago −6.91%α −4.16% · $67.00
- T+20 · 5mo ago +1.63%α +2.92% · $73.14
- T+60 · 3mo ago +14.51%α +13.27% · $82.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked protoporphyria (XLP) patients in the U.S., while noting that Phase 3 APOLLO topline data is expected in Q4 2026, with a CRL response and FDA decision expected by mid-2027. This is a procedural step that does not change the binary risk/reward of the upcoming Phase 3 readout and regulatory decision, and does not add new safety/efficacy data.
Key Facts
- EAP launched for bitopertin in eligible EPP/XLP patients aged 12+ in the U.S.
- Phase 3 APOLLO double-blind, placebo-controlled trial ongoing; topline data expected Q4 2026
- Disc Medicine expects to submit a CRL response with FDA decision by mid-2027
- Bitopertin is not approved in any jurisdiction; an earlier CRL prompted the updated timeline
- Company market cap ~$2.7B; analyst consensus is heavily bullish (95% buy-side)
Financial Impact
No financial data provided in this press release; the EAP is a non-revenue-generating program
Risk Factors
- Phase 3 APOLLO may fail to meet primary endpoint, as bitopertin previously received a CRL
- CRL response may be rejected by FDA, delaying or preventing approval beyond mid-2027
- EAP access does not guarantee favorable regulatory outcome or commercial adoption
- High cash burn for clinical-stage biotech with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304352 |
Track record
43 reports on IRON
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers